JIAHUI WANG^1,#, HONGCHENG GE^2,3,#, ZHENGYUAN YU^1,*, LINGZHI WU^1,*

Oncology Research, Vol.33, No.5, pp. 1033-1054, 2025, DOI:10.32604/or.2024.058256 - 18 April 2025

Abstract Lung cancer is a common cause of cancer-related death globally. The majority of lung cancer patients initially benefit from chemotherapy and immunotherapy. However, as the treatment cycle progresses and the disease evolves, the emergence of acquired resistance leads to treatment failure. Many researches have shown that non-coding RNAs (ncRNAs) not only influence lung cancer progression but also act as potential mediators of immunotherapy and chemotherapy resistance in lung cancer, mediating drug resistance by regulating multiple targets and pathways. In addition, the regulation of immune response by ncRNAs is dualistic, forming a microenvironment for inhibits/promotes More >

MICHELE MAFFEZZOLI^1,2,#, GIULIA CLAIRE GIUDICE^1,2,#,*, GIACOMO IOVANE^1,2, MARTINA MANINI^1,2, ELENA RAPACCHI¹, GIUSEPPE CARUSO¹, NICOLA SIMONI³, STEFANIA FERRETTI⁴, STEFANO PULIATTI⁴, DAVIDE CAMPOBASSO⁵, SEBASTIANO BUTI^1,2

Oncology Research, Vol.33, No.4, pp. 741-757, 2025, DOI:10.32604/or.2024.057278 - 19 March 2025

Abstract Background: immune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic urothelial carcinoma (mUC), significantly improving survival outcomes. However, a subset of patients do not respond to ICIs, prompting research into potential predictive factors. Commonly prescribed medications such as corticosteroids, proton-pump inhibitors (PPIs), antibiotics (Abs), antihypertensives, and analgesics may influence ICI effectiveness. Methods: we conducted a literature search on PubMed to investigate the impact of concomitant medications on the outcomes of patients with mUC, treated with ICIs. We selected the most relevant studies and performed a narrative review. Results: corticosteroids, PPIs and Abs have been associated More >

ZHIZHENG ZHANG^1,#, TAO LI^2,#, YUAN LI³, XI WANG⁴, HAO LIU⁵, XINYU SHEN⁵, ANN XU⁶, TIANSONG XIA^1,*, BO XU^7,*

Oncology Research, Vol.33, No.4, pp. 811-819, 2025, DOI:10.32604/or.2024.050505 - 19 March 2025

Abstract Background: Breast cancer is a prevalent malignant tumor affecting females, with treatment options including surgery, radiotherapy, chemotherapy, and endocrine therapy. Methods: This review synthesizes existing literature on breast cancer stem cells and their applications in breast cancer treatment. PubMed, Web of Science, and other relevant databases were systematically searched using keywords such as “breast cancer stem cells,” “immunotherapy,” “gene therapy,” and “cell therapy.” Studies published in English were included, and their findings were analyzed to provide insights into the characteristics and therapeutic potential of breast cancer stem cells. Results: Breast cancer stem cells exhibit unique properties More >

MARTA SANTOS¹, DIANA MARTINS^1,2,3,4, FERNANDO MENDES^1,2,3,4,5,*

Oncology Research, Vol.33, No.2, pp. 263-281, 2025, DOI:10.32604/or.2024.052207 - 16 January 2025

Abstract Background: Gastric Cancer (GC) is the 5th most prevalent and 4th most deadly neoplasm globally. Immunotherapy has emerged as a promising treatment approach in GC, potentially improving positive clinical outcomes while addressing the limitations of conventional therapies. GC immunotherapy modalities consist of adoptive cell therapy (ACT), cancer vaccines, and immune checkpoint inhibitors (ICI). Objectives: This systematic review aims to provide an overview of the advances in immune-based therapeutic approaches in GC, highlighting the potential of this therapy as a strategy for GC treatment. Methods: Key studies investigating several immunotherapeutic agents and combination therapies were searched in… More > Graphic Abstract

YAN LU^1,2,#, KANG WANG^3,#, YUANHONG PENG^3,4, MENG CHEN⁵, LIN ZHONG^3,4, LUJI HUANG^3,4, FU CHENG^3,4, XINDAN SHENG^4,6, XIN YANG^4,6, MANZHAO OUYANG^3,4, GEORGE A. CALIN^5,*, ZHIWEI HE^1,*

Oncology Research, Vol.33, No.1, pp. 103-121, 2025, DOI:10.32604/or.2024.057472 - 20 December 2024

Abstract Background: Immune checkpoint inhibitors play an important role in the treatment of solid tumors, but the currently used immune checkpoint inhibitors targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) show limited clinical efficacy in many breast cancers. B7H3 has been widely reported as an immunosuppressive molecule, but its immunological function in breast cancer patients remains unclear. Methods: We analyzed the expression of B7H3 in breast cancer samples using data from the Cancer Genome Atlas Program (TCGA) and the Gene Expression Omnibus (GEO) databases. MicroRNAs were selected using the… More >

WEI ZHANG^1,3,#, WEICHENG WANG^1,#, RUI WANG¹, XIAO HAN¹, LIJUN ZHU¹, WENJIE GUO^2,*, YANHONG GU^1,*

Oncology Research, Vol.33, No.1, pp. 225-234, 2025, DOI:10.32604/or.2024.050047 - 20 December 2024

Abstract Background: As a novel blocker of vascular endothelial growth factor receptor (VEGFR), fruquintinib has been approved for treating colorectal cancer (CRC). However, its dosage and therapeutic efficacy are limited by its widespread adverse reactions. Venetoclax, recognized as the initial inhibitor of B-cell lymphoma protein 2 (BCL2), has shown potential in boosting the effectiveness of immunotherapy against CRC. This study investigated the efficacy and mechanisms of fruquintinib combined with venetoclax in treating CRC. Methods and Materials: We developed a colon cancer mouse model with the CT26 colon cell line to demonstrate fruquintinib and venetoclax’s efficacy against tumors.… More > Graphic Abstract

RYUL KIM^1,#, JOO KYUNG PARK^2,#, MINSUK KWON³, MINAE AN⁴, JUNG YONG HONG¹, JOON OH PARK¹, SUNG HEE LIM^1,*, SEUNG TAE KIM^1,*

Oncology Research, Vol.33, No.1, pp. 57-65, 2025, DOI:10.32604/or.2024.049054 - 20 December 2024

Abstract Background: Immune checkpoint inhibitors (ICIs) are effective in a subset of patients with metastatic solid tumors. However, the patients who would benefit most from ICIs in biliary tract cancer (BTC) are still controversial. Materials and methods: We molecularly characterized tissues and blood from 32 patients with metastatic BTC treated with the ICI pembrolizumab as second-line therapy. Results: All patients had microsatellite stable (MSS) type tumors. Three of the 32 patients achieved partial response (PR), with an objective response rate (ORR) of 9.4% (95% confidence interval [CI], 2.0–25.2) and nine showed stable disease (SD), exhibiting a disease… More >

Evangelia Vlachou¹, Burles Avner Johnson 3rd^1,2, Elizabeth Guancial³, Kara A. Lombardo^1,2,4, Jean Hoffman-Censits^1,2

Canadian Journal of Urology, Vol.31, No.3, pp. 11875-11879, 2024

Abstract Introduction: Immune checkpoint inhibitors (ICIs) are approved for advanced urothelial cancer alone and as first line in combination with enfortumab vedotin. Platinum based chemotherapy which is another frontline choice is often not a treatment option for older patients due to comorbidities that increase with age. Despite ICIs being better tolerated compared to traditional chemotherapy little is known about their efficacy and toxicity in patients ≥ 90 years due to the rarity of this population in clinical trials. Our objective was to analyze the efficacy and toxicity of immune checkpoint inhibitors in patients ≥ 90 years.
Materials and… More >

Andrew S. Iskandar, Kevin K. Zarrabi, William J. Tester

Canadian Journal of Urology, Vol.31, No.4, pp. 11921-11930, 2024

Abstract Introduction: Renal cell carcinoma is as the most prevalent form of kidney cancer, with the clear cell subtype comprising approximately 75% of cases. The identification of predictive and prognostic biomarkers has emerged as a crucial area of research within the field. Despite advancements in treatment, metastatic renal cell carcinoma presents formidable challenges, with survival rates heavily dependent upon the optimal choice of treatment.
Materials and methods: This review summarizes the current literature regarding the prognostic and predictive value of biomarkers in patients with renal cell carcinoma. We conducted a comprehensive literature search to identify studies that reference… More >

Erdong Shen¹, Ting Pan¹, Pan Guo¹, Ke Chen¹, Rui Xu¹, Mei Yang¹, Dahe Zhan¹, Fang Fang¹, Qinghui Wu^1,*, Jianbing Hu^1,*

The International Conference on Computational & Experimental Engineering and Sciences, Vol.30, No.4, pp. 1-3, 2024, DOI:10.32604/icces.2024.012772

Abstract Objective
This study investigates the synergistic effects of a novel multifunctional nanoparticle on gastric cancer treatment through photothermal therapy, chemotherapy, and immunotherapy.

Method
Synthesize hollow mesoporous Prussian blue nanoparticles and load them with luteolin. Use exosomes to encapsulate the nanoparticles and modify the surface of the targeted peptide GX1. Detect the morphology of nanoparticles using a nanoparticle size analyzer and transmission electron microscopy. Use Coomassie Brilliant Blue to detect the effect of extracellular vesicle encapsulation. Detect the thermal conversion efficiency of nanoparticles under specific laser irradiation through infrared and ultraviolet spectroscopy, as well as the release rate… More >